-
RSL3: Translating Ferroptosis Mechanisms
2026-09-20
A thought-leadership guide to using RSL3 as a mechanistic GPX4 probe, validating ferroptosis rigorously, interpreting oncogenic RAS vulnerability, and advancing preclinical findings toward translationally meaningful decisions.
-
D-N-Acetylgalactosamine Workflow Guide
2026-09-19
D-N-Acetylgalactosamine (SKU B7904) provides a defined, high-purity reagent for aqueous or DMSO-based studies of glycoprotein composition, brain heteropolysaccharides, and related glycosylation workflows. It should not be used in ethanol-based preparations or for long-term storage of solutions; prepare working solutions close to use and store the solid at -20°C.
-
Irinotecan Beyond Cytotoxicity: Assay Design
2026-09-18
Irinotecan (CPT-11) is more than a topoisomerase I inhibitor: it can serve as a layered research perturbation linking tumor DNA damage with chemotherapy-associated gut–liver injury. This article translates recent mechanistic evidence into practical assay and workflow decisions for colorectal cancer research.
-
Cy3 NHS ester (non-sulfonated) Workflow Guide
2026-09-18
Cy3 NHS ester (non-sulfonated), SKU A8100, provides an orange fluorescent NHS ester for labeling accessible amino groups in proteins, peptides, and oligonucleotides. It is appropriate when an organic co-solvent is compatible with the biomolecule, but it should not be selected for water-only labeling or long-term storage of prepared dye solutions.
-
CDC42 Polarity Controls Intestinal Stem Cell Fate
2026-09-17
Zhang and colleagues show that CDC42-dependent epithelial polarity regulates the intestinal stem cell to transit-amplifying cell transition through a YAP/TAZ–Ereg–EGFR–mTOR cascade, rather than solely through canonical Wnt signaling. Genetic and pharmacological rescue experiments distinguish restoration of crypt proliferation and cell-fate balance from restoration of epithelial polarity, providing a useful framework for studying intestinal homeostasis.
-
G007-LK Tankyrase 1/2 Inhibitor: Research Workflows
2026-09-17
G007-LK provides a practical route to connect tankyrase enzymatic inhibition with AXIN stabilization, β-catenin degradation, and downstream growth phenotypes. This guide translates those mechanisms into reproducible Wnt reporter, protein, colony-formation, and Hippo pathway workflows for cancer biology research.
-
Topotecan in First-Line Small Cell Lung Cancer
2026-09-16
This reference article examines whether topotecan-based combinations could improve first-line treatment for small cell lung cancer, where initial chemotherapy responses are often followed by relapse and resistance. Its central contribution is a clinically focused synthesis of response and toxicity signals from phase II studies, emphasizing regimen design, reversible neutropenia, and the need for confirmatory trials rather than presenting a definitive practice-changing conclusion.
-
PBS Liposomes: Reliable Macrophage Controls
2026-09-16
Learn how PBS Liposomes (SKU K2722) improve interpretation of in vivo macrophage depletion studies by separating liposome exposure from clodronate-specific apoptosis. This scenario-driven guide covers experimental design, assay compatibility, storage, data interpretation, and practical vendor selection.
-
HDAC Inhibitors Repress NUT Function in NUT Carcinoma
2026-09-15
The reference study developed a dCas9-based reporter screen that identified chemically diverse HDAC inhibitors as suppressors of BRD4-NUT transcriptional activity. Panobinostat and IRBM6 reduced megadomain-associated oncogene expression, promoted differentiation, and suppressed tumor growth, supporting chromatin acetylation as a therapeutic vulnerability in NUT carcinoma.
-
Exemestane: From Mechanism to Model Design
2026-09-15
Exemestane is a steroidal aromatase inhibitor whose irreversible target engagement requires careful interpretation across enzyme, cellular, and translational breast cancer research. This guide connects aromatase biology with model selection, controls, and evidence-aware assay design.
-
ARCA Cy5 EGFP mRNA (5-moUTP) Workflow
2026-09-14
Use a dual-readout reporter to distinguish mRNA delivery from intracellular localization and EGFP translation in mammalian cells. This practical workflow combines fluorescence microscopy, flow cytometry, and formulation comparisons to support reproducible mRNA delivery system research.
-
Modeling Breast Cancer Relapse with Proliferation Tracing
2026-09-14
The reference study introduces a dual recombinase proliferation-tracing and ablation system in the spontaneous MMTV-PyMT mouse model. Selective removal of recently proliferating cells produces tumor regression followed by relapse from residual low-cycling populations, while single-cell RNA sequencing reveals stem-like cancer cells and protumor immune remodeling in recurrent tumors.
-
v-Agatoxin-IVA and Low-Affinity N-Type Ca Blockade
2026-09-13
Sidach and Mintz showed that v-Agatoxin-IVA remains a high-affinity P-type calcium channel blocker but can also inhibit N-type and other high-threshold currents at micromolar exposure. The study demonstrates why toxin selectivity must be interpreted alongside concentration, voltage dependence, gating kinetics, and neuronal preparation.
-
Docetaxel (A4394): Reliable Assay Design
2026-09-12
This scenario-driven guide explains how Docetaxel (SKU A4394) can support better-controlled viability, proliferation, and cytotoxicity assays. It covers mechanism, solvent compatibility, concentration planning, multidrug-resistance interpretation, and practical product selection.
-
Dissecting Cancer Drug Responses In Vitro
2026-09-12
Hannah Schwartz’s dissertation proposes a clearer way to interpret anticancer drug responses by separating proliferative arrest from actual cell killing. Its distinction between relative viability and fractional viability provides a practical framework for improving assay design, timing, and translational interpretation in cancer biology.